Actively Recruiting
Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC
Led by Guangdong Provincial People's Hospital · Updated on 2025-07-01
86
Participants Needed
1
Research Sites
200 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To study induction therapy with Nab-paclitaxel, Cisplatin and Pembrolizumab in patients with Locally Advanced HNSCC.
CONDITIONS
Official Title
Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed locally advanced Head and Neck Squamous Cell Carcinoma (oral cavity, oropharynx, laryngeal, hypopharynx) stage III or IVA without metastasis, previously untreated
- At least one measurable tumor lesion according to RECIST 1.1 criteria
- ECOG performance status of 0 or 1
- Men and women aged 18 to 70 years at informed consent
- Adequate liver, heart, and kidney function as defined by specified blood counts and organ function tests
- Female participants of childbearing potential must have a negative pregnancy test within 28 days before enrollment
- Willingness to provide informed consent and comply with study requirements
You will not qualify if you...
- Active or suspected autoimmune disease, Type I diabetes, hypothyroidism requiring hormone replacement, or skin diseases needing systemic treatment
- Systemic steroid therapy above 10 mg/day prednisone or equivalent within 14 days before enrollment
- Known active Hepatitis B, Hepatitis C, or HIV infection
- Active pulmonary tuberculosis
- Severe heart diseases including congestive heart failure, unstable angina, high-risk arrhythmias, myocardial infarction, or uncontrollable hypertension
- Pregnant or breastfeeding women
- Fertile patients unwilling or not using effective contraception
- Participation in another investigational study or use of investigational devices
- History of other invasive malignancies or unresectable cancer
- Receipt of live vaccine within 30 days before starting study therapy
- Any condition or abnormality that might interfere with study participation or results as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Actively Recruiting
Research Team
H
Haiqing Ma
CONTACT
S
Siyi Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here